Podcasts about biotalk

In this episode of BioTalk, Lara Mangravite, PhD, Executive Director of Digitalis Commons, joins the conversation to explore how scientific research is shifting in the U.S.—from centralized, institutional models to a more decentralized, innovation-driven landscape. She shares the mission of Digitalis Commons and explains how the organization is working at the intersection of technology, research, and public good to address systemic barriers in health and healthcare. Drawing from her recent article, "Notes on Catalyzing Health," Lara discusses the growing role of independent research institutions, the challenges of fragmentation, and why this moment calls for new leadership models and public-interest partnerships that can drive coordinated, high-impact solutions. Editing and post-production work for this episode was provided by The Podcast Consultant. Lara Mangravite, PhD, is Executive Director at Digitalis Commons, a nonprofit organization developing scalable, frontier-advancing solutions to critical problems in health. She previously served as President of Sage Bionetworks, where she led initiatives to build and share multi-modal human data for biomedical research. Lara earned her BS in Physics from Pennsylvania State University, her PhD in Pharmaceutical Chemistry from the University of California, San Francisco, and completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children's Hospital Oakland Research Institute.

In this episode of BioTalk, Amy C. Hay, Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), joins the conversation to explore the evolving landscape of cell and gene therapy. Amy shares insights from her extensive career in oncology care and innovation, highlighting the role CTMC—a joint venture between National Resilience and MD Anderson Cancer Center—is playing in accelerating the transition from discovery to commercialization. She discusses the current state of the industry, what disruption really means in this context, and how new business models can drive stability and impact for early-stage biotech companies. Amy also offers her perspective on how manufacturing must evolve to meet clinical demand, and how CTMC is positioned to lead in this next era of therapeutic development.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Amy C. Hay is the Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience and MD Anderson Cancer Center. She brings decades of experience in oncology care, strategic growth, and healthcare innovation to her role, where she leads business strategy, partnerships, and long-term growth initiatives. Prior to CTMC, Amy held leadership roles at Varian (a Siemens Healthineers company), MD Anderson Cancer Center, and several global consulting efforts focused on advancing cancer care. Her career spans work across the U.S. and internationally, with a focus on driving innovation, commercialization, and patient access in complex health systems.

In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what's changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.   Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC's Kenan-Flagler Business School. Editing and post-production work for this episode was provided by The Podcast Consultant.

In this episode of BioTalk, host Rich Bendis welcomes Sona Shah, CEO and Co-Founder of Neopenda, for an inspiring conversation on innovation, impact, and scaling medical technology in underserved markets. Sona shares how a formative experience teaching in rural Kenya ignited her passion for global health, leading to the creation of neoGuard, a wearable vital signs monitor tailored for low-resource settings. They discuss the engineering challenges of building clinical-grade hardware for hospitals with limited infrastructure, the company's growth from Maryland's Relevant Health accelerator, and the deployment of over 350 devices across East and West Africa. Sona also talks about Neopenda's next wave of products, lessons in balancing cost and quality, and the importance of community, resilience, and mission-driven entrepreneurship. Editing and post-production work for this episode was provided by The Podcast Consultant. Sona Shah is the CEO and Co-founder of Neopenda, a company dedicated to improving healthcare access in emerging markets. Neopenda develops innovative medical technologies—such as the neoGuard system—designed to help healthcare providers deliver high-quality care in low-resource settings. The company's mission is to make life-saving technology available where it's needed most. Sona's path into global health innovation began during a semester teaching primary school in Kenya, where she witnessed firsthand the challenges faced by under-resourced healthcare systems. That experience, paired with her background in biomedical engineering, inspired her to co-found Neopenda in 2015. Since then, the company has focused on delivering scalable, impactful solutions to countries including Kenya, Uganda, and Ghana, with a long-term goal of reaching the next billion people who could benefit from better access to care. She remains committed to advancing tech-driven healthcare solutions that make a meaningful difference in the world's most underserved communities.

During Episode 27 of Biotalk, Geoff Meyerson, CEO of Locust Walk, steps back to examine the macro forces shaping the biopharma landscape. After holding a bearish outlook since 2021, Geoff explains why he's finally shifting his stance and what could signal a true turnaround for biotech. He unpacks the “big three” market headwinds—regulatory hurdles from the IRA, FTC deal scrutiny, and high interest rates—and outlines how recent shifts, including rate cuts, new FTC leadership, and potential IRA reform, could spark renewed momentum, especially in M&A and rare diseases. Geoff also highlights previously underappreciated risks like HHS cuts and aggressive tariffs, which could stall progress if unresolved. With a balanced, apolitical lens, this episode offers candid insights into why policy matters for biotech investors, operators, and dealmakers—and what to watch for as 2025 unfolds. Tune in to understand the key inflection points and why Geoff sees the second half of 2025 as a potential breakout period for the industry. Full Transcript: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. In this episode, I want to zoom out and talk about the bigger picture — what's really driving the biotech market right now. In almost every meeting the past few months I have been asked my views on the market.  I decided that I am going to share my thoughts publicly. I fancy myself to be a free market limited government champion across all aspects of life. I do not comment politically nor believe it is my job to criticize or promote any politician or party. That said, the macro policies enacted by both parties directly impact the biopharma industry, and I believe it's important to analyze and comment on areas related to the life science industry. For all other issues, I subscribe to the University of Chicago's institutional neutrality, and it is my (and Locust Walk's) policy to not comment publicly. First a recap of why I was bearish starting fall 2021 when Locust Walk ran a webinar titled “Has Biotech Peaked”. Throughout 2022, 2023, and until September 2024, despite many market analysts predicting a turnaround, I maintained my bearishness because the 3 underlying headwinds that started blowing hadn't stopped or reversed, namely: Regulatory headwinds because of the IRA Transaction headwinds from an openly hostile FTC Monetary headwinds via high interest rates caused by high inflation Until these 3 drivers reversed, I didn't believe the market would improve beyond incremental changes. When in September 2024 the US Federal Reserve dropped rates by 50 bps, the rate tightening cycle had not only stopped but reversed. My changing perspective was independent of the pending election since the largest factor interest rates was starting to shift. In January 2025, Lina Khan exited the FTC and a new era of antitrust enforcement began. While far from perfect, it has been markedly more pro-business with a much less aggressive effort to block transactions. Locust Walk's Quarterly Market conditions detailed a 47% uptick in M&A by value and 35% by volume showing signs of life in this market even though I didn't anticipate any material improvement until 2H25 because it takes time for deals to come to fruition after the changeover in policy. I predicted M&A had the potential to transform the industry this year after years of suppression. I stand by this prediction and for everyone's sake I hope I'm right. The IRA pill fix is being discussed and because President Trump has come out in support, some form of it is likely to make its way into the reconciliation package of tax and regulatory cuts. I hope small molecules move to 13 years of exclusivity but bigger price discounts thereafter to remain budget neutral rather than meeting in the middle at 11 years, which I think would be quite problematic.

In this timely episode of BioTalk, returning guest Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News, joins host Rich Bendis to explore how sweeping changes in U.S. regulatory policy, workforce dynamics, and economic pressures are affecting the biotech industry in real time. Alex breaks down the potential consequences of FDA workforce cuts, particularly for small and mid-sized biotechs that depend on regulatory guidance, and offers perspective on how HHS and NIH budget proposals could reshape the national innovation infrastructure. The conversation covers everything from the impact of tariffs on manufacturing and supply chains to the slowing pace of M&A activity and venture capital investment trends. Alex also shares his insights on IPO strategy shifts, and whether the current biotech environment is poised for a rebound—or a broader realignment with global competitors. This is a must-listen episode for anyone navigating the uncertain waters of biotech in 2025. Editing and post-production work for this episode was provided by The Podcast Consultant. Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, as featured in our 2025 Q1 Report: Global Trends in Biopharma Transactions Report.  Japan saw modest market recovery, a $3.3B buyout of Mitsubishi Tanabe, and lighter licensing activity. Early-stage financings picked up as investors re-engaged. China shifted from IPO optimism to global deal-making as markets cooled. Notable trends included strong out-licensing ($17.6B), AstraZeneca's $2.5B investment, and Ascentage's NASDAQ debut backed by Takeda. Venture activity rebounded, driven by insider-led late-stage rounds. Korea drew attention with Orum's IPO, early-stage deals, and a growing focus on CDMO by major players.Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.

During Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends. Market Overview: The XBI fell 14% YoY, underperforming the NBI. Biotech weakness stemmed from tariff fears, FDA turnover, and HHS layoffs—pressuring small caps. Capital Markets: Capital raised dropped 33% from Q4. IPOs briefly reopened—large caps gained, small caps declined. Follow-ons fell 60%. PIPEs were weak, except Immunovant's $450M. Venture: Slight dip from Q4 but ahead of all 2023 quarters. Late-stage rounds led, with 11 mega-rounds (Eikon $351M, Kardigan $300M) making up over half the total. M&A & Licensing: M&A hit $25.2B across 13 deals, focused on Ph2+ assets (e.g., J&J/Intra-Cellular). Licensing stayed strong, favoring clinical-stage programs. Europe: Strategic deal value reached $13B, led by Zealand-Roche and Gubra-AbbVie. Venture hit $1.2B—90% in Series A rounds like Verdiva ($411M) and Windward ($200M). Outlook: Regulatory uncertainty and rates may delay M&A, though late-stage and commercial deals could gain momentum. Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe reflect on their journey over the past year, discussing key themes and insights gained from their guests. They explore the humanistic approach to healthcare, the impact of AI in drug development, common threads among successful individuals, personal growth through conversations, and the importance of leadership and mentorship in the industry. The episode concludes with exciting plans for future series focused on drug development and global healthcare innovations.Thanks to CREO Consulting for hosting this episode!https://creoconsulting.com/ Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/  Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/  TakeawaysEvery sample is a person, a patient, a loved one.Embrace the fear, take more risks.The importance of human connection in drug development.AI is becoming integral in drug discovery and development.Successful individuals often wish they had taken more risks.Leadership in the industry is about raising others up.Mentorship plays a crucial role in professional growth.Personal growth can come from listening and engaging with others.Innovative approaches are essential in addressing industry challenges.KeywordsBioTalk, drug development, AI, mentorship, leadership, podcast, healthcare, innovation, personal growth, industry insights

What does it take to establish Maryland as a powerhouse for biotech commercialization? In this episode of BioTalk with Rich Bendis, Dr. Deborah Hemingway, Founder and Managing Partner of Ecphora Capital, shares her insights on the current investment landscape in the BioHealth Capital Region. She discusses the strategic advantages that make Maryland uniquely positioned for success, the critical gaps that must be addressed, and how state and local governments can provide essential support through tax credits, grants, and economic incentives. Dr. Hemingway also highlights Ecphora Capital's impact, having deployed $15 million in the last two years, and reveals the firm's strategy for future investments, including SPVs and a dedicated fund. With deep experience in medtech commercialization, strategic partnerships, and early-stage investing, she offers valuable perspectives on where the industry is headed in 2025 and how companies can thrive in an evolving biotech ecosystem. Tune in for a compelling conversation on innovation, investment, and the future of biotech in the BioHealth Capital Region. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Deborah Hemingway is the Founder and Managing Partner of Ecphora Capital, a medtech venture capital firm in Baltimore, Maryland. Ecphora Capital leverages first-look access at world-class medical research and manufacturing institutions and is the first and only entity to achieve the top level of a state tax credit program that refunds 75% of their investment.  Additionally, Dr. Hemingway has profound involvement in the entrepreneurial landscape, having founded, invested in, and held board positions for 53 startup companies over twenty years. She has meticulously sharpened her acumen in medical device commercialization, strategic growth, and investing. She is on the board of directors for Mi-Helper and Novel Microdevices. Dr. Hemingway holds a Ph.D. in biophysics from the University of Maryland, College Park.

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China, highlighting key trends and developments shaping the region as featured in our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff leverages extensive conversations with strategics and investors worldwide to provide insights into global biotech deal-making. Key topics include: Japan's Recovery in 2024: A rebound in licensing activity reached $2.1B in Q4, driven by preclinical and small molecule deals. Venture financing grew 20%, with Series C and D rounds leading the charge. China's Strategic Transactions: Licensing deal value surged to $47B, driven by out-licensing, regulatory improvements, and NewCo formations. US investors are highly valued, with reverse mergers and IPOs becoming popular strategies for accessing US capital markets. Key Themes: Japan's focus on in-licensing signals interest in earlier-stage innovation, while China's “fallen angel” assets provide US companies with cost-effective opportunities. Looking ahead to 2025, Geoff discusses how stabilization in Japan and China's growing innovation will shape global biotech, despite regulatory and geopolitical challenges. Subscribe or follow Biotalk on Apple Podcasts | Spotify.   

In this episode of BioTalk, host Rich Bendis is joined by Amitabh Varshney, Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Together, they explore the groundbreaking advancements in artificial intelligence and health computing driven by the University of Maryland (UMD). Dean Varshney discusses the launch of the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) earlier this year. He shares insights into the vision behind AIM, the strategic hiring of new faculty, the allocation of seed grants, and the development of academic programs in AI, all solidifying UMD's position as a leader in this rapidly evolving field. The conversation also delves into the University of Maryland Institute for Health Computing (UM-IHC), which recently marked its two-year anniversary. Dean Varshney highlights the institute's achievements, including its partnerships with organizations like the FDA and NIH, patent submissions, and collaborations with AstraZeneca and 20/20 Gene Systems. He explains how UM-IHC's efforts are reshaping the intersection of health and technology. Rich and Dean Varshney discuss UMD's commitment to innovation and its role in tackling national challenges through interdisciplinary education, cutting-edge research, and collaborations with industry partners, government agencies, and research institutions. They also reflect on the university's integral role within the BioHealth Capital Region and its contribution to advancing scientific discovery, economic growth, and regional leadership in biotech and health innovation. Tune in to hear how UMD's focus on AI and health computing is shaping the future of education, research, and collaboration. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Amitabh Varshney is Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Varshney is currently exploring applications of virtual and augmented reality in several areas, including education, healthcare, and telemedicine. His research focuses on exploring the applications of high-performance visualization in engineering, science, and medicine. He has worked on a number of research areas including visual saliency, summarization of large visual datasets, and visual computing for big data. He has served in various roles in the IEEE Visualization and Graphics Technical Committee, including as its Chair (2008–12). He received the IEEE Visualization Technical Achievement Award in 2004. He is a Fellow of IEEE and a member of the IEEE Visualization Academy.

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the insights from the comprehensive report and offers a forward-looking perspective on what 2025 may bring for the biotech industry. Key topics include: Capital Markets Performance: The XBI ended flat, down 0.2%, underperforming the S&P 500's 24% gain. However, 2024 saw a 156% increase in capital raised compared to 2022, with IPO and follow-on financings improving in Q4. Venture Financing Trends: Q4 venture financing remained stable at ~$4B across 43 deals, with Series A and B rounds leading. Mega-rounds grew, including Kailera's $400M Series A and Metsera's $215M Series B. Strategic Transactions: Licensing deal value surged 135% in Q4, driven by early-stage deals, while M&A activity slowed, with no deals exceeding $5B. Regional Highlights: Europe and Asia saw a rise in venture and licensing activity, with Asia's cross-border deals and NewCo formations becoming key trends. This will be discussed further in a separate podcast. Market Outlook for 2025: With a new FTC chair, M&A and licensing deals are expected to rise in 2025. IPO markets will improve with gradually reduced interest rates, though risk aversion remains with private mega-rounds persisting to reduce financing risk. Geoff offers advice for navigating the current market and highlights Asia's growing role in global biotech. Stay tuned for our upcoming podcast on Asian markets.Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify.   

In this episode of BioTalk with Rich Bendis, Dr. Kolaleh Eskandanian, Vice President and Chief Innovation Officer at Children's National Hospital, discusses her work driving pediatric healthcare innovation. Dr. Eskandanian introduces the BARDA SPARK Accelerator, a groundbreaking initiative focused on advancing medical countermeasures for children, and explains how it aligns with Children's National's mission to lead in pediatric healthcare innovation. She also highlights the unique challenges in developing pediatric medical countermeasures and the importance of partnerships with organizations like Rainbow Babies, Mass General, and others. Additionally, Dr. Eskandanian shares insights into the hospital's role in fostering innovation through the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children's National Research and Innovation Campus. Join us for an engaging conversation about the future of pediatric healthcare, the opportunities for innovation, and how the SPARK Accelerator is paving the way for advancements that will improve the lives of children worldwide. Editing and post-production work for this episode was provided by The Podcast Consultant. Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P. is Vice President and Chief Innovation Officer at Children's National Hospital, reporting to hospital's Executive Vice President, Physician-In-Chief and Chief Academic Officer. In this capacity, she oversees the Office of Innovation Ventures, the Sheikh Zayed Institute's R&D operations, and has a leadership role in the development of the Children's National Research and Innovation Campus (opening 2020). She is also the executive director of the FDA-funded National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focused on accelerating the path to market for pediatric devices. Eskandanian works with a large network of small and large businesses, nonprofits and government agencies –addressing the unmet medical needs of children. She is the producer of an annual innovation competition that supports small businesses who demonstrate the ability to address a significant medical need in the pediatric space. Eskandanian's expertise includes the full spectrum of product development activities, having held management positions at Accenture, a global management consulting firm, where she directed major product launches for clients. Eskandanian is the co-PI on the FDA-funded Global Pediatric Clinical Trials Network grant and the CTSI-CN lead of the Orphan Product Accelerator.  Eskandanian's own innovations are in the market space, used by millions. She is the lead inventor of the first-ever adverse event reporting system, initially deployed in a research academic environment. This technology and its derivatives have now been in the market for over 10 years. She has had leadership roles in the development of the first web-based trouble entry management system for a Fortune 100 company in the telecommunications sector. She has been a key contributor in securing over $40 million in government funding for two large research enterprises. Prior to joining Children's National, Kolaleh held positions with Intelsat, Accenture and Georgetown University. Her background is in mechanical engineering with a PhD in operations science and an MBA from American University Kogod School of Business.

In this episode of BioTalk, Bill Tompkins, President and CEO of the Montgomery County Economic Development Corporation (MCEDC), discusses the strategies driving Montgomery County's position as a leading bioscience hub. Bill highlights MCEDC's role in reinforcing the region's standing as the third-largest bioscience cluster in the U.S. and shares insights into the new Institute for Health Computing. He also introduces two new venture funds—the Technology Innovation Fund and the Founders Fund—designed to accelerate innovation and support local entrepreneurs. Bill outlines MCEDC's priorities for the upcoming year, emphasizing economic growth, investment opportunities, and fostering collaborations that make Montgomery County a thriving ecosystem for business and life sciences. Bill Tompkins is the President and Chief Executive Officer of the Montgomery County Economic Development Corporation (MCEDC), based in Rockville MD. He leads a team of twenty-five diverse professionals who work to fulfill the mission of making Montgomery County one of the best, most diverse and equitable places to be in business in the country. Bill was previously Executive Vice President and Chief Operating Officer and has been with MCEDC since January of 2019. Bill has a seasoned background in marketing, business operations, strategic planning, and nonprofit management, with most of his career serving as a senior executive in the media and entertainment industries with Fortune 500 companies. Bill also ran a consulting practice which advised companies on strategic business opportunities and brand transformation strategies. From May 2014 until August 2015, Bill was Vice President, Advertising and Marketing at The Philadelphia Tribune. He made a strategic investment in The Tribune to help ensure the long-term sustainability of Black media in the US. In July 2012, he was named President and CEO of the National Newspaper Publishers Association, a Washington based organization, which represents over two hundred Black owned and operated newspapers across the nation. Bill joined the Eastman Kodak Company in 2000 as Chief Marketing Officer for the Entertainment Imaging Business unit and became Vice President and General Manager of the Motion Picture Film Group while also serving as a corporate vice president. Prior to Kodak, Bill spent nineteen years from 1982 until 2000 at The Washington Post Newspaper in a variety of executive positions. His most recent position there was Vice President of Marketing with most of his career spent in the Advertising and Circulation Departments. Bill has been in active leadership positions on several nonprofit Boards including the Mosaic Theater Company of DC where he is Treasurer and the former Chair of the Board, Rockville Economic Development (REDI), Worksource Montgomery and the Advisory Boards of the Universities at Shady Grove and Montgomery Moving Forward. He was previously Chairman, National Kidney Foundation, National Capital Area, member, Board of Directors, California Chamber of Commerce, the Advertising Council, the Studio Theatre, The Washington Convention and Visitors Association, The Boys and Girls Clubs of Greater Washington, the American Black Film Festival Advisory Board, and The Helen Hayes Awards Committee. He is also a member of the Executive Leadership Council, and a graduate of Leadership Washington. Bill is a member of the Economic Club of Washington, the Executive Leadership Council, and a graduate of Leadership Washington. Bill received his MBA from the Harvard Business School where he was a General Motors Fellow and received his BA in Economics, magna cum laude from Tufts University. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

In this episode I share a couple short clips from my conversation with Chad Briscoe and Greg Austin from BioTalk Unzipped (www.biotalkunzipped.com). We chat about a variety of topics including artificial intelligence and challenges with cell therapy development. You can hear the entire conversation on the BioTalk Unizipped podcast or YouTube channel in January. For now, enjoy these clips from the upcoming show! Links discussed in the show: BioTalk Unzipped main page BioTalk Unzipped YouTube channel You can connect with me on ⁠LinkedIn and send me a message⁠⁠ Send me a message⁠⁠ Sign up for my newsletter⁠

On this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President of ARNAY Sciences and a pioneer in RNA therapeutics. Sudhir's extensive career spans over three decades, during which he has made groundbreaking contributions to the field, including developing gapmer antisense technology, immune modulation approaches, and, in recent years, designing cyclic structures of DNA and RNA for therapeutic applications. In their conversation, Sudhir recounts his journey from his early days in nucleic acid research to becoming a leading innovator in RNA therapeutics. He delves into the origins of the gapmer technology, its impact on antisense drug development, and the lessons learned from his time Idera Pharmaceuticals. He also shares insights into his latest work on cyclic RNA/DNA structures and discusses his vision for the future of nucleic acid therapeutics. He concludes by offering practical advice to entrepreneurs aspiring to break into the biotech space and sharing his thoughts on the future of RNA science. Join us for a deep dive into the world of RNA therapeutics with one of its most influential figures.Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 1:34 What inspired you to focus specifically on RNA therapeutics, and how did your whole journey here begin?  3:04 Can you provide more details about the initial insight behind the development of the gapmer technology, which has been transformational for the space?  5:34 What lessons did you learn from your experience at Ionis (formerly Isis) that you would apply to your current work?  13:54 How are you thinking about commercializing the cyclic RNA/DNA structures you have developed at your company RNA Sciences?  23:40 Beyond the cyclic structures, what other innovations or areas of focus do you see on the horizon for nucleic acid therapeutics?  23:23 What advice would you give your early self starting out as an entrepreneur and innovator in the biotech space? 

In this episode of BioTalk, host Rich Bendis welcomes Ric Hughen, CEO of Linshom Medical, and Talia Feldman, Software Engineer at Linshom Medical, to discuss their groundbreaking advancements in respiratory monitoring technology. As the main winners of the 2024 Crab Trap Competition at the 10th Annual BioHealth Capital Region Week, Ric and Talia share Linshom's mission to improve patient safety through their innovative and accessible respiratory monitoring devices. Ric explains how Linshom is addressing critical gaps in respiratory monitoring by bringing operating-room-quality data to patient bedsides and homes. Talia shares insights from the engineering side, highlighting the challenges and breakthroughs in developing reliable and user-friendly technology. The conversation explores Linshom's roots in the BioHealth Capital Region and how its partnerships and resources have been instrumental to the company's growth. Talia reflects on her experience presenting at the Crab Trap Competition, and Ric discusses how this recognition aligns with Linshom's broader visibility and growth objectives. Looking ahead, Ric and Talia provide a glimpse into Linshom's future, including upcoming milestones and advancements that promise to further revolutionize respiratory care. Don't miss this episode filled with innovation, collaboration, and a vision for transforming patient safety. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Richard Hughen's thirty years of medical device experience spans three Fortune 500 and three start-up companies with two successful exits to date. He is currently CEO of Linshom Medical, a start-up that is first to deliver operating room quality respiratory data to the patient bedside and home. Ric was an investor and member of the executive team that built start-up CSA Medical, from a technology license (U.S. Navy) through product development, animal trials, clinical trials, five FDA clearances, CE mark, three rounds of funding ($50M), commercial growth and a 2019 sale to Steris. Ric was Managing Director of LearnWare, a life science focused e-learning start-up, which was successfully built and sold to a private equity fund. He is currently a reviewer for the National Science Foundation's SBIR/STTR program, an Entrepreneur in Residence for Johns Hopkins Tech Ventures, an advisory board member of George Mason University's Bioengineering Alliance and a site miner for TEDCO at the University of Maryland Medical Center in Baltimore. Earlier in his career, Ric led various senior management, marketing, training and sales teams for Johnson & Johnson, BD, Abbott and Cordis. Ric holds MBA and BS degrees from The Pennsylvania State University. Talia Feldman is a software engineer at Linshom Medical, an innovative healthcare technology company at the forefront of transforming respiratory monitoring. Talia received a B.S. in Computer Science with a concentration in Artificial Intelligence from the University of Delaware. Upon graduation she worked as a software engineer in the Maritime Division at Leidos. Now combining her technical skills with a passion for innovation, Talia supports Linshom Medical's development of providing continuous predictive respiratory monitoring to improve patient care.

In this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel Brog, Senior Vice President, for an insightful discussion on the implications of the 2024 U.S. election results for the biotech industry. The conversation delves into: What Trump's victory could mean for the biotech sector. The potential impact on the HHS and FDA under RFK's leadership. How figures like Elon Musk and Vivek Ramaswamy might influence healthcare policy (DOGE dynamics). We take a balanced approach, covering the potential positive and negative outcomes, implications, and our perspectives on these topics. Our analysis is based on actual statements made and prior activities, focusing specifically on the impacts for biotech. While we aim to minimize bias, we acknowledge that personal perspectives inevitably influence conclusions. Please note this was recorded Friday, November 23, before the announcements of the FDA Commissioner, Surgeon General, and Head of the CDC later that day. Join us as we explore how these political outcomes could shape the future of biotech and healthcare innovation. We welcome your thoughts and look forward to engaging in further discussions as events unfold. Email us at ceo@locustwalk.com to share your insights or questions.Subscribe or follow Biotalk on Apple Podcasts | Spotify.

In this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel Brog, Senior Vice President, for an insightful discussion on the implications of the 2024 U.S. election results for the biotech industry. The conversation delves into: What Trump's victory could mean for the biotech sector. The potential impact on the HHS and FDA under RFK's leadership. How figures like Elon Musk and Vivek Ramaswamy might influence healthcare policy (DOGE dynamics). We take a balanced approach, covering the potential positive and negative outcomes, implications, and our perspectives on these topics. Our analysis is based on actual statements made and prior activities, focusing specifically on the impacts for biotech. While we aim to minimize bias, we acknowledge that personal perspectives inevitably influence conclusions. Please note this was recorded Friday, November 23, before the announcements of the FDA Commissioner, Surgeon General, and Head of the CDC later that day. Join us as we explore how these political outcomes could shape the future of biotech and healthcare innovation. We welcome your thoughts and look forward to engaging in further discussions as events unfold. Email us at ceo@locustwalk.com to share your insights or questions.Subscribe or follow Biotalk on Apple Podcasts | Spotify.

In this episode of BioTalk with Rich Bendis, Dr. Eric Edwards, Co-Founder and CEO of MedPhlow, shares how his innovative company is reshaping emergency medicine through cutting-edge drug delivery systems. Dr. Edwards discusses his journey from co-founding Kaléo, where he helped develop life-saving products like AUVI-Q, to leading MedPhlow, a subsidiary of Phlow Corp. Based in Richmond, VA, MedPhlow is dedicated to addressing critical challenges in essential medicine delivery, with its first product focused on improving outcomes during sudden cardiac arrest. Dr. Edwards explains the groundbreaking technology behind MedPhlow's platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow's next milestones in its mission to make emergency medicine more efficient and accessible. As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company's clinical program strategy; and Vice President – Innovation, overseeing Kaleo's research and development pipeline and overall new product strategy.   Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications.   Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care. Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.  

On this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.  David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason's models differ from existing approaches, and the benefits they offer in accelerating drug development. They also delve into the evolving role of AI in drug discovery, the transformative potential it holds, and the critical challenges the industry will face as the field scales.    Reflecting on the importance of diverse thinking in this fast-evolving space, David notes, "Diversity of opinions is critical to making things work. You need diverse perspectives to distill the truth before it's delivered to the customer, who is highly educated and smart. Without tough questions being asked openly, things can fall apart quickly."  David also offers three key pieces of advice for entrepreneurs looking to enter the intersection of AI and life sciences today.Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 1:14 To start, nothing in your background said AI or disease biology, how did you decide to work in this space and what motivated you to co-found CytoReason? 5:50 Why hadn't anyone done this before with molecular data? And how was it different from what was being done? 6:54 Did the vision for CytoReason stay the same or evolve? 7:30 The big question, where do you get the data and is it proprietary? 10:28 What do CytoReason's models do? What is the benefit and how does this help drug development? 13:50 How are you thinking about building your business out to tackle the industry? 22:00 How do you foresee the role of AI evolving in drug discovery and development, and what challenges do you anticipate as the field grows? 28:55 What advice would you give to entrepreneurs looking to enter the intersection of AI and life sciences today?

Join us for an insightful episode of BioTalk as Rich Bendis speaks with Eric Mayton, CEO of Cerillo, one of the recent winners at the Crab Trap competition during the 10th Annual BioHealth Capital Region Week. Cerillo, based in Charlottesville, VA, is making waves in microbiome research and biological product development with its innovative tools designed to tackle variability challenges and enhance data collection efficiency.   In this episode, Eric shares Cerillo's mission to combat Eroom's Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo's co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.   Learn how being located in the southern part of the BioHealth Capital Region has supported Cerillo's growth and hear about the company's future plans to further accelerate biological research. Don't miss this conversation about the innovations driving a new era in cellular analytics.   Eric Mayton is the President, CEO, and Chairman of the Board at Cerillo, a Charlottesville, VA based cellular analytics firm focused on increasing the efficiency, reproducibility, and standardization of data collection in scientific research and product development. Eric spent the first decade of his career managing academic and commercial laboratories before earning his MBA from the University of Richmond in 2017.   After stints in private equity and management consulting, Eric returned to the biotech industry in 2020 as CEO of Cerillo, a University of Virginia spin-out. Eric holds a B.S. in Chemistry from the University of Virginia, a M.S. in Biochemistry from Virginia Commonwealth University, and a M.B.A from the University of Richmond.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS' national and international footprint, and the significant partnerships with organizations like Children's National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

In this episode of BioTalk, Rich Bendis speaks with Dr. Frank Gupton, Co-Founder of Phlow and CEO of the Medicines for All Institute, about his pioneering efforts to improve pharmaceutical manufacturing and global access to essential medications. Dr. Gupton shares how Phlow is addressing vulnerabilities in the U.S. pharmaceutical supply chain by producing critical medicines domestically, and how the Medicines for All Institute is reshaping the way drugs are made by reducing costs and streamlining production. Drawing on his extensive experience in the pharmaceutical industry, Dr. Gupton discusses the ongoing challenges of ensuring that lifesaving medicines reach those in need worldwide. The discussion also touches on the future of pharmaceutical manufacturing, from emerging technologies like continuous processing to green chemistry's role in creating more sustainable production methods. Dr. Gupton provides insight into how partnerships and collaboration are vital to accelerating these innovations. Join the conversation to hear about the impactful work being done to transform drug manufacturing and access on a global scale. Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton's research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University. Dr. Gupton's research efforts have focused on streamlining pharmaceutical processes, particularly in the area of active ingredients, by employing the principles of process intensification which include the use of innovative chemistry, novel continuous manufacturing platforms, and new and more efficient catalysts for pharmaceutical applications. The research group's efforts are guided and driven based on both financial and economic impact that can be derived from this effort. Dr. Gupton is the recipient of the 2018 American Chemical Society Award for Affordable Green Chemistry, and in the same year, he received the Presidential Award for Green Chemistry. In 2019 he received the Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry from the ACS Green Chemistry Institute Pharmaceutical Round Table. These awards were associated with Professor Gupton's work on the development of a highly efficient process to produce nevirapine, a first-line treatment in HIV therapy.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).  

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.   In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:   Biotech capital markets: The XBI rose 7% in Q3, outperforming the S&P 500, driven by strong clinical readouts and strategic deals, with six IPOs showing strong investor demand.  Private biotech markets: Venture financing dropped to $3.9B across 41 deals, with average deal size decreasing, while Series A and B deals led the market, showing renewed investor interest in early-stage companies.  Strategic transaction activity: Licensing deal value fell by 22%, and M&A shifted to smaller deals focusing on early clinical-stage opportunities, with global deal values remaining down.  Market outlook and advice for the months ahead: Locust Walk expects continued momentum in Q4 due to further Fed rate cuts, advises careful cash management, and foresees a stronger recovery by 2025.  We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you.  Subscribe or follow Biotalk on Apple Podcasts | Spotify.   

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., sits down with Peter Ronco, Chief Executive Officer of Emmes, a global full-service Clinical Research Organization (CRO). Peter discusses his transition from leading roles at Janssen R&D and Bristol Myers Squibb to guiding Emmes' strategic direction and operations.   Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.   The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.   About Peter Ronco: Peter Ronco is the CEO of Emmes, with extensive global experience in pharmaceutical development. He oversees the strategic and operational aspects of Emmes, a leading CRO operating in over 30 countries. Prior to Emmes, Peter held senior roles at Janssen R&D and Bristol Myers Squibb.   Tune in to BioTalk for a focused discussion with Peter Ronco on Emmes' growth, AI in clinical research, and the future of global drug development. Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes Brad Sibbald, Vice President of Kelly Science and Clinical, and Sarah Porter, Vice President of Government Solutions at Kelly Services. Together, they explore the critical trends and strategies shaping the biotech and government workforce landscapes, with a particular focus on the BioHealth Capital Region (BHCR). Kelly Services, a global leader in workforce solutions, plays a pivotal role in connecting talent with opportunities across various industries, including science, engineering, technology, and telecommunications. Brad and Sarah provide valuable insights into how Kelly Services is adapting to the evolving needs of the biotech sector, from commercial enterprises to government agencies. The discussion covers various topics, including the current talent landscape in the BHCR, strategies for maintaining a robust pipeline, and the challenges of retaining top talent in an increasingly competitive market. Additionally, we learn about Kelly's upcoming virtual job fair in September (https://bit.ly/3yMuiRm), an event for those looking to connect with opportunities in the biotech sector and the 2024 Kelly Global Re:work Report (https://bit.ly/3SSVhBl), offering listeners valuable insights into the future of work and workforce trends globally. About Brad Sibbald: Brad Sibbald is the Vice President of Kelly Science and Clinical, with over 15 years of experience in workforce solutions and consultative services. With a background in biochemistry and a passion for innovation, Brad is committed to driving forward-thinking solutions in the biotech industry. About Sarah Porter: Sarah Porter is the Vice President of Government Solutions at Kelly Services, leading the sales and operations for Kelly Government Solutions. With nearly 20 years of experience in the government industry, including a role at the NIH, Sarah has a deep understanding of the complexities of workforce solutions in the federal sector. Tune in to BioTalk for an insightful discussion with Brad Sibbald and Sarah Porter as they explore workforce trends, talent strategies, and the evolving landscape of biotech and government solutions in the BioHealth Capital Region and beyond. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

In this special episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., hosts a compelling discussion with three groundbreaking guests from South Africa: Johann de Bruyn, CEO of TASK, Ethan Hunter, Chief Operations Officer at Immobazyme, and Dr. Carla Eksteen, Postdoctoral Research Fellow at Stellenbosch University. Together, they share their journey of connecting South Africa's biotech scene with the BioHealth Capital Region, showcasing how innovation transcends borders.   Johann de Bruyn opens the conversation by introducing TASK Applied Science and its collaborative relationship with the U.S. He explains the genesis of Bio Centrifuge Africa, a business plan competition inspired by the BioHealth Capital Region's Crab Trap, designed to bridge the gap between South Africa's emerging biotech sector and the established BHCR.   Ethan Hunter, co-founder of Immobazyme, discusses his company's pioneering work in precision fermentation and the growing impact it has across various industries. He reflects on the significance of winning Bio Centrifuge Africa and the exciting opportunity to compete in the 9th Annual Crab Trap in Maryland this September.   Dr. Carla Eksteen shares her research journey in cancer immunotherapy and the vital role her work plays in advancing healthcare in South Africa. She talks about the opportunities provided by Bio Centrifuge Africa and her upcoming trip to Maryland as part of the competition winners.   This episode offers a fascinating look at how South African innovators are making their mark on the global biotech stage and emphasizes the power of international partnerships in driving the industry forward.   About Johann de Bruyn: Johann de Bruyn is the CEO of TASK Applied Science, committed to integrating Africa into the global clinical research landscape. With a diverse background in management, Johann is passionate about advancing healthcare and elevating Africa's role in global clinical research.   About Ethan Hunter: Ethan Hunter is the Chief Operations Officer and co-founder of Immobazyme, a South African biotechnology company specializing in precision fermentation. With a strong foundation in plant biotechnology and molecular biology, Ethan is leading Immobazyme's innovative efforts in the biotech industry.   About Dr. Carla Eksteen: Dr. Carla Eksteen is a Postdoctoral Research Fellow at Stellenbosch University, focusing on cancer research and immunotherapy. With significant experience in tackling chemotherapy treatment resistance and tumor immunogenicity, Dr. Eksteen is dedicated to advancing precision oncology in South Africa.   Tune in to BioTalk for an enlightening discussion with Johann de Bruyn, Ethan Hunter, and Dr. Carla Eksteen as they share their experiences and vision, linking South African biotech innovation with the BioHealth Capital Region.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).  

On this episode of Biotalk, Locust Walk's Andy Meyerson welcomes Dr. Lindsay Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech, a company focused on licensing and developing high-potential marketed and development-stage drugs. Lindsay shares his journey from physician to biotech entrepreneur and outlines Fortress Biotech's strategy of licensing high-potential marketed and development-stage drug candidates, avoiding early-stage technologies. They discuss how Fortress capitalizes on inefficiencies in the drug development market, such as acquiring drugs approved abroad but not in the US, and the role of AI in improving drug search and evaluation efficiency. Despite concerns about macroeconomic risks and changes in healthcare spending, Lindsay believes Fortress can navigate these challenges by being a low-cost producer of drug candidates. Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 1:26 Lindsay, you have had an interesting and varied career across finance in life sciences. I always find successful people's career arc fascinating – How did your career develop, and what lead you to your current role at Fortress Biotech? 3:58 What spurred your interest in life sciences? 5:26 What we hear over and over in our current discussions with investors is an interest in identifying high-quality assets from within pharma or biotechs that can be spun out into new companies. This has been gaining in attractiveness over the last 3 years as investor focus increases on clinical-stage assets. What I find interesting about this shift is that Fortress' strategy has been to do this since its founding. This leads me to a couple of questions: What do you think about this current investor trend? 10:15  How did you arrive on the Fortress business model? 14:11 What do you see as the overall implications for everyone now that so many people are hunting for the same opportunities? 17:12 What potential do you see for AI in revolutionizing drug discovery and development at Fortress Biotech? 19:52 What is your current view on the biotech market, and what trends do you foresee shaping the industry in the coming years? 22:09 Given the dynamic nature of biotech, how is Fortress Biotech positioning itself to navigate future challenges and opportunities?

On this episode of Biotalk, Locust Walk's Andy Meyerson welcomes Dr. Lindsay Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech, a company focused on licensing and developing high-potential marketed and development-stage drugs. Lindsay shares his journey from physician to biotech entrepreneur and outlines Fortress Biotech's strategy of licensing high-potential marketed and development-stage drug candidates, avoiding early-stage […]

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs.   Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.   Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.   The conversation highlights examples of ARPA-H investments and milestones achieved, as well as the processes involved in determining future programs and investment priorities. Craig and Jenica also discuss the unique Entrepreneur in Residence (EIR) program and how it supports ARPA-H projects.   About Craig Gravitz: Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H).  Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. He is a licensed attorney and has previously serviced as a contracting officer.   About Jenica Patterson, Ph.D.: Jenica Patterson, Ph.D is a Portfolio Lead at ARPA-H within the Project Accelerator Transition Innovation Office (PATIO) and leads the Sprint for Women's Health. Formerly Dr. Patterson served as the Director of the Technology Transfer and Transition (T3X) Division in the PATIO office, where she oversaw public-private partnerships for transition and the small business program for ARPA-H. Dr. Patterson received her Ph.D in Neuroscience at the University of Maryland, Baltimore County (UMBC) and served as a Science and Technical Advisor at the Defense Advance Research Project Agency, and a Program Director at NIH prior to joining ARPA-H.   Tune in to BioTalk for an informative discussion with Craig Gravitz and Jenica Patterson as we explore the innovative work of ARPA-H and its impact on health research and development.

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. Alex joins the podcast to discuss the latest Top 10 U.S. Biopharma Clusters list, where the BioHealth Capital Region secured its #3 ranking for the second consecutive year.   The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions have sustained their scientific excellence and the long-lasting impact of pioneering efforts.   We explore the criteria used for ranking U.S. biopharma clusters, including NIH funding, venture capital funding, laboratory space, and the number of jobs. Alex provides insights into the methodologies and data sources, such as the NIH RePORT database, PitchBook, and regional life sciences groups, that underpin these rankings.   About Alex Philippidis: Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.   Tune in to BioTalk for an insightful discussion with Alex Philippidis as we explore the latest trends and developments in U.S. biopharma clusters, and the ongoing success of the BioHealth Capital Region.  

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry.   Matt shares key findings from CBRE's recently released 'U.S. Life Sciences Talent Trends' report for 2024 (https://www.cbre.com/insights/books/us-life-sciences-talent-trends-2024), offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector.   The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole.   We also hear about how CBRE has contributed to the growth and development of the life sciences ecosystem in the BHCR, with Matt sharing examples of key projects and initiatives that stand out. Looking ahead, he outlines CBRE's plans for further expanding and enhancing its presence and services in the region, highlighting upcoming projects and investments.   Matt addresses the dynamic nature of the life sciences real estate market, discussing some of the biggest challenges in the BHCR and how CBRE is positioning itself to address these challenges while capitalizing on new opportunities.   About Matt Gardner: Matt Gardner leads CBRE's Advisory Life Sciences practice in the U.S., including occupier and investor leasing as well as sales. Before joining CBRE, he served as CEO and co-founder of the California Biomanufacturing Center. He has co-founded and served on the boards of multiple incubators across the U.S., including the Maryland Technology Development Center. Matt has a rich history of supporting life sciences companies and has contributed to numerous publications and NPR's Biotech Nation.   Tune in to BioTalk for an informative discussion with Matt Gardner as we explore the future of life sciences real estate and talent trends, and CBRE's pivotal role in supporting the growth of the BioHealth Capital Region.  

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: The XBI remained flat in Q2, diverging from the bullish S&P 500, with fewer IPOs but more capital for later-stage companies. Private biotech markets: Venture financing rebounded with $5.5 billion across 44 deals, though the industry is divided between companies able to raise capital and those struggling. Strategic transaction activity: M&A and licensing deal values stayed consistent with Q1, focusing on Phase 2 companies and notable ex-US acquisitions. Market outlook and advice for the months ahead: Locust Walk expects continued positive momentum, advises careful cash use, notes non-dilutive capital accessibility, and predicts gradual recovery through 2024 with a stronger 2025. We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify.    Timestamps: 0:39 Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook 8:31 Our Advice for the Current Market Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2024 Second Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Locust Walk maintains proprietary transaction and finacning databases and each quarter our deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook To provide some structure, I will first cover biotech capital markets, touching on both public and private market performance over the past quarter. I will then transition into strategic transaction activity, covering both M&A and licensing. Please note, the full report published on the Locust Walk website is over 60 slides, so while I will do my best to summarize, as always, I encourage you to check out the full report for additional detail. To download this report, please go to locustwalk.com and go to our “Insights” page. The XBI traded relatively flat across the second quarter, diverging meaningfully from the broader S&P 500, which saw bullish gains. Key drivers of this divergence were the XBI being more impacted by the higher-than-anticipated CPI reading in April relative to the S&P 500 and the record-breaking growth of AI/tech companies. One stunning non-biotech stat to consider: Nvidia alone accounts for more than a third of the S&P 500's gains in 2024. In terms of public fundraising, IPO activity slowed in the second quarter, with only 3 such deals. The weakened macroeconomic outlook and generally poorer performance of first-quarter IPOs reduced market demand for new companies. From my perspective, public biotech markets remain closed to all except a selection of late-stage companies with de-risked approaches, ideally accompanied by insider support and sufficient near-term news flow. Follow-on market activity also cooled from Q1, but interestingly, the average capital raised ($178M) in Q2 is up over 47% relative to the 2023 quarterly average, highlighting the accessibility of large chunks of capital for more de-risked later stage companies with strong data. Venture financing continued its rebound from Q1, with the 44 deals summing to $5.

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff […]

In this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer. Host Rich Bendis is the President and CEO of BioHealth Innovation, Inc., dedicated to accelerating biohealth opportunities and fostering innovation across the BioHealth Capital Region of Maryland, Washington D.C., and Virginia….and the world.   Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas' critical role in Tunisia's development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts.   We explore the Department of State-US funded CURES project in Tunisia, examining its goals, progress, and future objectives. Ambassador Hood elaborates on the significance of U.S. funding for projects like CURES and the broader impact on both nations. BioHealth Innovation, Inc. (BHI) is a contractor to FHI 360, supporting the CURES project to assist Tunisia in building its life science research, technology transfer, and commercialization capabilities.   The conversation also covers other key partnerships and projects that the U.S. supports in Tunisia, aimed at fostering research and technology transfer. Ambassador Hood shares insights into these collaborations and his vision for the future of U.S.-Tunisia relations in science and technology.   "The collaborative efforts between the U.S. and Tunisia in scientific research and technology transfer are crucial for advancing innovation and fostering economic growth. The programs we discuss on BioTalk are a testament to the great work happening in this field. I want to thank Ambassador Hood for joining us and sharing his invaluable insights on these important initiatives," says Rich Bendis.   About Joey R. Hood: Joey Hood was confirmed by the U.S. Senate on December 22, 2022. He has held several leadership positions in the U.S. Department of State's Bureau of Near Eastern Affairs, including Acting Assistant Secretary. His extensive diplomatic career includes assignments in Iraq, Kuwait, Saudi Arabia, Yemen, and Qatar. Prior to the Foreign Service, Mr. Hood was a Fulbright scholar in Burkina Faso and worked at a bank in Vermont. He earned a Master's degree from the Fletcher School at Tufts University and a Bachelor's degree from Dartmouth College.   Tune in to BioTalk for an insightful conversation with Ambassador Joey R. Hood as we explore the dynamics of U.S.-Tunisia cooperation in science and technology, and its potential to drive innovation and progress.

Join us for an episode of BioTalk with Rich Bendis featuring Dr. Bradley Maron, Senior Associate Dean for Precision Medicine and Executive Co-Director of the University of Maryland-Institute for Health Computing at the University of Maryland School of Medicine. With his extensive background in cardiovascular research and precision medicine, Dr. Maron offers a wealth of knowledge and innovative perspectives.   In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard and Maryland/University of Maryland, highlighting the unique attributes and opportunities within each.   Dr. Maron introduces the Institute for Health Computing (IHC), explaining its creation, mission, and strategic partnerships with the University System of Maryland and Montgomery County. He outlines the significance of data science in improving health and wellness, addressing its increasing role and challenges.   We learn about the IHC's approach to bringing learning and healthcare directly to communities, illustrated by an example of their methodology: analyze, innovate, prevent, treat, and adapt. Dr. Maron discusses how the IHC aims to become an economic driver for the University System of Maryland, the state, the BioHealth Capital Region, and the nation, fostering startups, spinouts, commercialization efforts, and entrepreneurial activities.   Dr. Maron outlines the Institute's ambitious goals for the first five years and the range of services to be provided. He also details the decision to establish the IHC in Montgomery County, describing its new facilities and the county's supportive role.   Tune in to BioTalk for an informative discussion with Dr. Bradley Maron as we explore the future of precision medicine and the impactful work of the Institute for Health Computing.  

Radiological Health (CDRH) at the US Food and Drug Administration (FDA). With a distinguished background as a board-certified ophthalmologist and epidemiologist, Dr. Tarver is at the forefront of transforming the evaluation and inclusion of medical devices in underserved and underrepresented populations. In this episode, Dr. Tarver introduces the FDA and the CDRH Division, explaining the definition of a medical device by FDA standards. She discusses the creation of the Chief Transformation Officer role within the FDA, highlighting its importance and the strategic vision behind it. We explore the critical importance of diversity, equity, and inclusion (DEI) in evaluating medical devices, and how these efforts are essential for ensuring equitable healthcare for all. Dr. Tarver introduces the innovative “Home as a Health Care Hub” initiative by the FDA/CDRH, explaining its potential to revolutionize healthcare delivery. Dr. Tarver also addresses the broader transformation needed in the healthcare system to ensure no one is left behind, emphasizing the role of partnerships in achieving this goal. She delves into the role of Virtual Reality (VR) and Artificial Intelligence (AI) in making the home a central hub for healthcare, discussing this ambitious initiative's current status, challenges, and long-term objectives. Additionally, we touch on Dr. Tarver's impressive background, including her leadership roles within the CDRH and her academic achievements at Spelman College and Johns Hopkins University. Finally, we discuss the value of having the FDA in the BioHealth Capital Region and its impact on advancing healthcare innovation. Tune in to BioTalk for an insightful discussion with Dr. Michelle Tarver as we explore the future of medical devices, healthcare transformation, and the pivotal role of the FDA in shaping a more inclusive and innovative healthcare landscape. Dr. Michelle Tarver is a board-certified ophthalmologist and epidemiologist, serving as the Deputy Center Director for Transformation. In this role, Dr. Tarver facilitates the development, implementation, and direction of CDRH's transformative projects and strategic initiatives. Under her leadership, CDRH is advancing efforts to include underserved and underrepresented populations in the evaluation of medical devices. Her CDRH career has included many leadership roles, including the Deputy Director of the Office of Strategic Partnerships and Technology Innovation and the Program Director of Patient Science and Engagement. Dr. Tarver received a B.S. in Biochemistry from Spelman College in Atlanta, GA and completed the M.D./Ph.D. program at The Johns Hopkins University School of Medicine and Bloomberg School of Public Health. 

Join us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation.   In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field.   We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA.   Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role,  Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future.   Additionally, Dan talks about Rich Bendis's role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region.   Finally, Dan outlines SSTI's current initiatives and projections for the future, offering a glimpse into the ongoing efforts to support prosperity through science, technology, innovation, and entrepreneurship.   Experience an engaging discussion with Dan Berglund, a leader who has dedicated his career to advancing tech-based economic development and is now ready to embark on a new chapter.   Tune in to BioTalk to gain valuable insights from one of the most influential figures in the field and learn about the future of tech-based economic development.   Dan Berglund is the President and CEO of SSTI, a nonprofit organization dedicated to improving initiatives that support prosperity through science, technology, innovation and entrepreneurship. SSTI is the most comprehensive resource available for those involved in technology-based economic development. Leading SSTI since its inception in 1996, Mr. Berglund has helped SSTI develop a nationwide network of practitioners and policymakers dedicated to improving the economy through science, technology and innovation. SSTI works with this network to assist states and communities as they build tech-based economies, conduct research on best practices and trends in tech-based economic development, and encourage cooperation among and between state and federal programs. Prior to joining SSTI, Mr. Berglund worked as a consultant and for the Ohio Department of Development in a variety of positions, including Acting Deputy Director of the Division of Technological Innovation.

On this episode of Biotalk, Locust Walk's Geoff Meyerson welcomes Stephen Sands, former Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group, and currently Senior Advisor at Lazard, a renowned name in global financial services. Together, they explore Stephen's journey into life sciences finance, his transition into financial and management roles within healthcare, his mentors, and how these relationships impacted his career. Geoff and Stephen also tackle the evolution of banking in today's healthcare investment landscape, highlighting specialization's role. They cover navigating challenges and strategies in investments, including banking structures, capital markets, trends, IPOs, banks' role in deals, and future biopharma investment trends. Stephen offers valuable advice throughout the episode, specifically addressing CEOs on navigating the changing winds of the industry, providing insights into the intricacies of healthcare finance and investment strategies in the biopharma sector. Subscribe or follow Biotalk on Apple Podcasts | Spotify.    Timestamps: 1:26 To start, I'm eager to learn about your journey into the life sciences, and more specifically, to the financial and management side of healthcare. You to use your degrees in Biology and Chemical Engineering in this way. Tell us about your store and what brought you through the arch of your career. 7:11 Can you speak about the evolution of healthcare banking from your experience? 15:22 You have seen a lot of cycles in your career. How do you think this cycle compares to prior cycles? 20:45 What's the secret to building relationships and and what's your strategy for building such a robust M&A franchise? 23:52 What biopharma trends do you think will be emerging over the next 3-5 years? 27:57 How do you navigate these changing winds and what advice would you give to a CEO of a smaller company? 30:29 Are you a free agent, retired, board member? What's next for you?

On this episode of Biotalk, Locust Walk's Geoff Meyerson welcomes Stephen Sands, former Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group, and currently Senior Advisor at Lazard, a renowned name in global financial services. Together, they explore Stephen's journey into life sciences finance, his transition into financial and management roles within healthcare, his mentors, […]

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.   In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:   Biotech capital markets: Highlighting XBI's recovery, strong market indicators, and increased PIPE activity since Q2 2023.  Private biotech markets: Saw the second-best deal quarter since 2021, yet activity remains flat compared to 2021's robust fundraising  Strategic transaction activity: Observing big pharma's large acquisitions, with US M&A lower than Q4 while EU firms showed strong activity.  Market outlook and advice for the months ahead.  We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify.    Timestamps: 0:36 Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook 6:23 Our Advice for the Current Market Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2024 First Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook To provide some structure, I will first cover biotech capital markets, touching on both public and private market performance over the past year. I will then transition into strategic transaction activity, covering both M&A and licensing. Please note, the full report published on the Locust Walk website is over 60 slides, so while I will do my best to summarize, as always, I encourage you to check out the full report for additional detail. To download this report, please go to locustwalk.com and go to our “Insights” page. Q1 of this year continued last quarter's recovery of the XBI and saw a sharp upswing at the end of February on the heels of multiple positive data readouts. The XBI has since normalized but ended Q1 above prior 2023 highs. In support of this positive momentum, we saw several strong indicators of a potential recovery for the public biotech markets. Q1 saw an increase in follow-on offering's volume and deal size (up $8.1B from $3.5B in Q4'23), and a meaningful increase in PIPE volume and size (up $2.6B from $1.7B in Q4'23). We're seeing a trend of increasing PIPE activity that started in Q2 2023, reflecting companies' preference to reduce financing risk by securing capital prior to data announcements, despite the cost of providing less favorable terms. For example, Avidity raised a $400M PIPE, a week before they announced positive data from their Phase 1/2 trial for their lead asset. IPO volume also doubled from Q4, which is positive, although there has been limited activity after the first half of Q1 and the companies going public largely remain limited to later-stage companies. I believe the IPO window is still relatively shut and the public market for early-stage companies will remain challenging, with the two preclinical IPOs, Metagenomi and Fractyl Health, struggling to perform already. To a lesser degree, the private US biotech markets saw some recovery in Q1 with 15 rounds >$100M, the second-best quarter in aggregate deal value since 2021, and nearing the 2023 peak seen in Q3. Overall, activity is still relatively flat when compared to the robust fund...

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.   In this episode, Geoff […]

Join us in this episode of BioTalk with Rich Bendis as we delve into the Baltimore ecosystem with Kory Bailey, Chief Ecosystem Officer (CEO) of UpSurge Baltimore, a trailblazing organization dedicated to fostering equitable economic growth and innovation. Kory Bailey brings over a decade of leadership experience from both early-stage startups and big tech. He has emerged as a thought leader on equitable economic growth and a champion for Baltimore's tech ecosystem. As the CEO of UpSurge Baltimore, Kory is spearheading the vision for Baltimore to become the first Equitech hub globally, pioneering a new model for American innovation. In this discussion, Kory unveils UpSurge Baltimore's mission: to cultivate a thriving tech ecosystem for innovators, founders, and talent by fostering culture and connectivity and mobilizing regional and national assets around Baltimore startups. From exploring what drew him to Baltimore to discussing the evolution and unique aspects of UpSurge, Kory shares insights into the philanthropic landscape in Baltimore and initiatives like the Equitech Accelerator, Techstars, KHU, and CareFirst. He also delves into the primary challenges facing Baltimore and UpSurge's short-term goals focused on accountability, awareness, investment, and early-stage support. Join us as we envision Baltimore's future in the next five years and the pivotal role UpSurge Baltimore plays in shaping it. Tune in now to be part of the conversation driving equitable economic growth and innovation in Baltimore's tech ecosystem.

Discover the Future of Healthcare with John Sackett, Executive Vice President & COO of Adventist Healthcare, on BioTalk with Rich Bendis. In this episode, John Sackett shares his insights into the changing landscape of healthcare delivery. From his early days as an administrative assistant to his current role, John's journey offers invaluable lessons on leadership and innovation in the healthcare industry. Join us as we explore Adventist Healthcare's role in the BioHealth Capital Region (BHCR) and explore the transformative changes in healthcare delivery. Gain valuable insights into the challenges and innovations reshaping healthcare post-COVID and learn how Adventist Healthcare is leading the way in patient-centered care. In a candid and inspiring segment, John opens up about his personal journey of managing cystic fibrosis while excelling in his career. Discover the remarkable advancements in the treatment and life expectancy of CF patients, highlighting the power of innovation and resilience in overcoming adversity. Don't miss this enlightening episode as we navigate the evolving landscape of BioHealth Innovation and the BHCR Region with John Sackett, a visionary leader shaping the future of healthcare.

Join us for an engaging episode of BioTalk as we sit down with Lance Kawaguchi, Chief Executive Officer of the Cure Brain Cancer Foundation. Lance's career trajectory from global finance to non-profit leadership is as inspiring as it is impactful, driven by a personal mission to combat brain cancer following the loss of his mother.   In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for brain and rare cancer charities, culminating in a historic journey to the South Pole. We recognize Lance's leadership achievements, including ringing the Nasdaq bell twice as a cancer charity CEO, and his success in bringing the GBM AGILE Clinical Trial Platform from the US to Australia, accelerating breakthrough research efforts.   We also discuss Lance's strategic plans for growth and impact in the BioHealth Capital Region, driving forward the Cure Brain Cancer Foundation's mission. Additionally, we introduce the esteemed medical and scientific advisory committee steering the foundation's groundbreaking initiatives.   Join us for an insightful discussion as we uncover Lance Kawaguchi's transformative journey and the innovative strides being made in the fight against brain cancer. Tune in to BioTalk and be inspired!  

Are you prepared to discover a transformative shift in orthopedic innovation? Join us in this episode of BioTalk with Rich Bendis as step into the world of Nanochon with CEO Ben Holmes.   Nanochon is leading the charge in the field of medical technology, reimagining the landscape of joint injury treatment. Their inventive implant not only restores damaged cartilage but also fosters fresh tissue growth. Utilizing cutting-edge 3-D printing technology and groundbreaking material, Nanochon's implant serves as both a resilient orthopedic load-bearing device and a scaffold for tissue regeneration. This advancement is poised to redefine patient recoveries, trim healthcare costs, and establish new benchmarks in cartilage rehabilitation.   In this episode, we learn about Nanochon's beginnings, the uniqueness of their technology, the individuals constituting their team, their funding strategies, and the challenges they've overcome.   Don't miss this episode as we venture into the frontier of advanced medical solutions with Nanochon. Tune in now and be part of the conversation reshaping the future of joint health.  

In this episode of BioTalk with Rich Bendis, we're joined by three guests from Solaxa: CEO & Founder Christian Walker, Chief Operating Officer Luis T. Gutierrez, Jr., and Chief Commercial Officer Jennifer Butler. Solaxa is a pioneering biotech company with a mission to revolutionize the treatment of cerebellar ataxias and acute nerve injuries caused by trauma and chemotherapy.   Discover the compelling story behind Solaxa's choice to establish its roots in Montgomery County and how the BioHealth Capital Region has played a crucial role in its growth. Learn how Solaxa's team was assembled, including the inspiring success stories of Luis and Jennifer, both part of the BioHealth Innovation and Montgomery County Maryland's Executive in Residence program.   Hear how Solaxa is making a difference in the world of neurology with SLX-001, a drug showing immense promise in treating cerebellar ataxias. Dive into their innovative approach, including the development of their treatment for cerebellar ataxias.   Additionally, discover how Solaxa's pioneering efforts in this field provide hope for healing. Join us for an enlightening discussion on the future of neurology, innovative treatments, and the remarkable journey of Solaxa.   CEO & Founder Christian Walker has focused his last twenty years pursuing the commercialization of nerve injury solutions. Christian's fundraising experience spans raising money for start-ups, being a start-up venture capitalist, and securing significant non-dilutive financing through grants. At Christian's prior start-ups, Christian was directly responsible for securing $11M in venture financing.   While at Toucan Capital, he served as Principal of a $140 million venture capital fund focused on early-stage investments in stem cells and regenerative medicine. At Johns Hopkins and Walter Reed, he helped secure $22.5M in non-dilutive grants.   Luis T. Gutierrez, Jr. serves as Chief Operating Officer of Solaxa while also serving as an Executive in Residence with BioHealth Innovation.   In both roles, he leverages his 25+ years of expertise in helping novel medical technologies with scientific and clinical promise transition to becoming successful commercial enterprises.    He previously served in executive roles with Veranex, Theralink Technologies, Aptiv Solutions, and Covance.   Chief Commercial Officer Jennifer Butler has 25 years of broad biotechnology industry experience. Her commercial roles at MedImmune, AstraZeneca, and Innate have equipped her with a deep understanding of commercial execution at large and emerging biopharma. Notably, Jen launched Innate's first commercial product in a rare oncology population. Jennifer also is also serving as an Executive in Residence with BioHealth Innovation.  

Have you ever wondered about the true impact of Artificial Intelligence (AI) in the BioHealth industry? In this episode of BioTalk with Rich Bendis, we have the privilege of hosting Dr. Juergen Klenk, a Principal at Deloitte and a Board Member at BioHealth Innovation. Dr. Klenk brings a wealth of expertise and experience with a unique background combining formal scientific training and entrepreneurial ventures.   Join us as we embark on an insightful discussion about the current state of AI in the BioHealth industry, diving deep into the realities and challenges of this cutting-edge technology. Dr. Klenk shares his interest in AI and the reasons behind its increasing prominence in the field. We explore the historical origins of the AI hype cycle and how we've reached the stage we're in today.   Discover tangible examples that illustrate AI's true value, benefits, and impact in BioHealth. Dr. Klenk sheds light on the underlying key technologies that power AI and the associated challenges and risks.   Looking to the future, we examine the outlook for AI in the coming months, years, and even this decade. Will the AI hype continue, or will we witness substantial breakthroughs and transformations? Dr. Klenk offers valuable insights into what organizations can and should do to ride the AI wave effectively.   Don't miss this engaging conversation with Dr. Juergen Klenk as we navigate the exciting world of AI in the BioHealth industry. Tune in now to gain a deeper understanding of AI's reality and its potential to shape the future of healthcare and research.